[go: up one dir, main page]

EE200100549A - Meetod fibroosi ravimiseks integriini alfa-4 subühiku antagonistide abil - Google Patents

Meetod fibroosi ravimiseks integriini alfa-4 subühiku antagonistide abil

Info

Publication number
EE200100549A
EE200100549A EEP200100549A EEP200100549A EE200100549A EE 200100549 A EE200100549 A EE 200100549A EE P200100549 A EEP200100549 A EE P200100549A EE P200100549 A EEP200100549 A EE P200100549A EE 200100549 A EE200100549 A EE 200100549A
Authority
EE
Estonia
Prior art keywords
treating fibrosis
integrin alpha
subunit
antagonists
subunit antagonists
Prior art date
Application number
EEP200100549A
Other languages
English (en)
Inventor
Gotwals Philip
R. Lobb Roy
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200100549A publication Critical patent/EE200100549A/et
Publication of EE05662B1 publication Critical patent/EE05662B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200100549A 1999-04-22 2000-04-21 Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine EE05662B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13084799P 1999-04-22 1999-04-22
US13721499P 1999-06-01 1999-06-01
PCT/US2000/010781 WO2000064474A1 (en) 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit

Publications (2)

Publication Number Publication Date
EE200100549A true EE200100549A (et) 2002-12-16
EE05662B1 EE05662B1 (et) 2013-06-17

Family

ID=26828876

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100549A EE05662B1 (et) 1999-04-22 2000-04-21 Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine

Country Status (31)

Country Link
US (3) US6652856B2 (et)
EP (1) EP1173201B1 (et)
JP (3) JP5483515B2 (et)
KR (3) KR20070102760A (et)
CN (3) CN1332714C (et)
AT (1) ATE298249T1 (et)
AU (1) AU783054B2 (et)
BG (2) BG65578B1 (et)
BR (1) BR0010669A (et)
CA (1) CA2370814C (et)
CY (1) CY1106046T1 (et)
CZ (1) CZ301636B6 (et)
DE (1) DE60020955T2 (et)
DK (1) DK1173201T3 (et)
EA (1) EA006681B1 (et)
EE (1) EE05662B1 (et)
ES (1) ES2243259T3 (et)
GE (1) GEP20063844B (et)
HK (1) HK1041452B (et)
HU (1) HU226383B1 (et)
IL (5) IL145898A0 (et)
IS (1) IS2259B (et)
MX (1) MXPA01010612A (et)
NO (1) NO330221B1 (et)
NZ (2) NZ515053A (et)
PL (1) PL198975B1 (et)
PT (1) PT1173201E (et)
RS (2) RS50086B (et)
SK (1) SK287328B6 (et)
TR (1) TR200200027T2 (et)
WO (1) WO2000064474A1 (et)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20063844B (en) * 1999-04-22 2006-06-12 Biogen Idec Inc Using antagonist of integrin alpha-4 subunit for treatment of fibrosis
HUP0202568A3 (en) 1999-06-01 2009-11-30 Biogen Idec Inc A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
ES2233383T3 (es) * 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
CA2406024C (en) * 2000-03-17 2012-05-22 Avocet Polymer Technologies, Inc. Methods for improving size and appearance of a wound
JP2004512345A (ja) * 2000-11-02 2004-04-22 スミスクライン・ビーチャム・コーポレイション 受容体アンタゴニスト−脂質コンジュゲートおよびそれを含有するデリバリービヒクル
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
CN1838942A (zh) * 2003-07-11 2006-09-27 普罗医药公司 递送疏水性药物的组合物和方法
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
JP5037134B2 (ja) * 2003-10-17 2012-09-26 レハブ アル−ジャマル 組織修復
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
EP1773128A2 (en) * 2004-08-02 2007-04-18 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
EP2034830B1 (en) * 2006-05-25 2014-09-03 Biogen Idec MA Inc. Anti-vla-1 antibody for treating stroke
EP2537529B1 (en) 2007-08-02 2018-10-17 Gilead Biologics, Inc. Loxl2 inhibitory antibodies and uses thereof
NZ629204A (en) 2012-02-16 2016-09-30 Santarus Inc Anti-vla1 (cd49a) antibody pharmaceutical compositions
WO2013147076A1 (ja) * 2012-03-28 2013-10-03 国立大学法人広島大学 インテグリンα8β1の機能を阻害する事による線維化の抑制
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
EP3755723A4 (en) * 2018-02-23 2021-12-22 Chugai Seiyaku Kabushiki Kaisha CROSS SPECIES ANTI-LATENT TGF-BETA-1 ANTIBODIES AND METHOD OF USE
PE20221447A1 (es) 2019-08-28 2022-09-21 Chugai Pharmaceutical Co Ltd Anticuerpos anti-tgf-beta 1 latente y metodos de uso
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
HK1007682A1 (en) 1992-01-13 1999-04-23 Biogen Idec Ma Inc. Treatment for asthma
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
AU687790B2 (en) * 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
EP0804237B8 (en) * 1994-01-25 2006-11-08 Elan Pharmaceuticals, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
WO1995028961A1 (en) * 1994-04-26 1995-11-02 Kanebo, Ltd. Remedy for rheumatoid arthritis
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
JPH10330268A (ja) * 1997-05-26 1998-12-15 Kureha Chem Ind Co Ltd ピラノピラノン化合物含有ｈｓｐ４７合成抑制剤
EP1504764B1 (en) * 1997-08-08 2008-10-08 The Regents Of The University Of California Treatment of liver fibrosis with antibodies against alpha V beta 6 integrin
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
GEP20063844B (en) * 1999-04-22 2006-06-12 Biogen Idec Inc Using antagonist of integrin alpha-4 subunit for treatment of fibrosis
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑

Also Published As

Publication number Publication date
KR20070102760A (ko) 2007-10-19
HU226383B1 (hu) 2008-10-28
EE05662B1 (et) 2013-06-17
US20050281818A1 (en) 2005-12-22
CN1596979A (zh) 2005-03-23
CN1679935A (zh) 2005-10-12
WO2000064474A1 (en) 2000-11-02
MXPA01010612A (es) 2003-09-04
RS50086B (sr) 2009-01-22
IL206829A0 (en) 2010-12-30
IL182908A (en) 2010-11-30
RS20080471A (sr) 2010-12-31
DK1173201T3 (da) 2005-09-12
EP1173201B1 (en) 2005-06-22
PT1173201E (pt) 2005-08-31
JP2007182453A (ja) 2007-07-19
US20020182213A1 (en) 2002-12-05
ATE298249T1 (de) 2005-07-15
CZ301636B6 (cs) 2010-05-12
HK1041452B (en) 2005-10-14
NZ541431A (en) 2008-01-31
SK287328B6 (sk) 2010-07-07
HK1041452A1 (en) 2002-07-12
BG65578B1 (bg) 2009-01-30
SK15202001A3 (sk) 2002-09-10
CN1356911A (zh) 2002-07-03
CY1106046T1 (el) 2011-04-06
KR100746522B1 (ko) 2007-08-07
NO20015122L (no) 2001-12-21
BR0010669A (pt) 2002-02-19
JP2002542300A (ja) 2002-12-10
US6652856B2 (en) 2003-11-25
CA2370814A1 (en) 2000-11-02
BG106118A (en) 2002-05-31
PL198975B1 (pl) 2008-08-29
NZ515053A (en) 2004-02-27
CN1191860C (zh) 2005-03-09
BG66149B1 (bg) 2011-08-31
JP5483515B2 (ja) 2014-05-07
IL145898A (en) 2007-07-24
KR100837715B1 (ko) 2008-06-13
HUP0201015A3 (en) 2004-12-28
BG110115A (en) 2008-12-30
YU74901A (sh) 2004-07-15
AU4480000A (en) 2000-11-10
AU783054B2 (en) 2005-09-22
JP2014065747A (ja) 2014-04-17
IL182908A0 (en) 2007-08-19
IS2259B (is) 2007-06-15
US20040037827A1 (en) 2004-02-26
CA2370814C (en) 2010-07-06
NO330221B1 (no) 2011-03-07
TR200200027T2 (tr) 2002-07-22
DE60020955T2 (de) 2006-05-11
HK1076379A1 (zh) 2006-01-20
EA006681B1 (ru) 2006-02-24
IL206830A (en) 2013-06-27
KR20020000221A (ko) 2002-01-05
CN1332714C (zh) 2007-08-22
HUP0201015A2 (hu) 2002-07-29
NO20015122D0 (no) 2001-10-19
WO2000064474A8 (en) 2001-04-05
EP1173201A1 (en) 2002-01-23
IL206829A (en) 2013-06-27
ES2243259T3 (es) 2005-12-01
CZ20013754A3 (cs) 2002-07-17
DE60020955D1 (de) 2005-07-28
IL206830A0 (en) 2010-12-30
EA200101116A1 (ru) 2002-04-25
GEP20063844B (en) 2006-06-12
CN100360183C (zh) 2008-01-09
IL145898A0 (en) 2002-07-25
IS6105A (is) 2001-10-11
PL351916A1 (en) 2003-06-30
KR20070050979A (ko) 2007-05-16

Similar Documents

Publication Publication Date Title
EE200100549A (et) Meetod fibroosi ravimiseks integriini alfa-4 subühiku antagonistide abil
DE60101339D1 (de) Stimulierung des knochenwachstums mit peptidderivaten von thrombin
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
LU93274I2 (fr) Elotuzumab
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ATE327004T1 (de) Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40
MY132529A (en) Paroxetine hydrochloride anhydrate
SE0001914L (sv) Förbättring av Peyronies sjukdom
DE60031714D1 (de) Thrombopoietin-mimetika
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
TR200002939T2 (tr) Paroksetin maleat
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
RU99112883A (ru) Способ лечения привычного вывиха плеча
EA200100041A1 (ru) Способ лечения

Legal Events

Date Code Title Description
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20150421